A drug called teprotumumab, which blocks a specific protein in the eye socket, has been shown to reduce bulging eyes and double vision in people with active thyroid eye disease, offering a more targeted treatment than steroids.
Claim Context
Teprotumumab, a monoclonal antibody targeting IGF-1R, is associated with significant reductions in proptosis and diplopia in patients with active thyroid eye disease, representing a major therapeutic advance over traditional immunosuppressive approaches.
“teprotumumab is the first approved monoclonal antibody targeting IGF-1R. By blocking the IGF-1R signaling pathway, it inhibits inflammation and fibrosis, significantly improving ocular symptoms and signs. It demonstrates particularly pronounced efficacy in reducing proptosis and resolving diplopia.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of all randomized trials of teprotumumab could quantify its overall effect size on proptosis reduction and safety profile across populations.
A systematic review and meta-analysis of all published randomized controlled trials comparing teprotumumab (10 mg/kg IV every 3 weeks for 24 weeks) to placebo or glucocorticoids in adults with active TED (CAS ≥3), measuring mean change in proptosis (mm), diplopia resolution rate, and adverse events over 24–52 weeks.
A randomized controlled trial could establish whether teprotumumab causes greater improvement in proptosis than glucocorticoids in active TED.
A multicenter, double-blind, active-controlled trial of 200 adults with active TED (CAS ≥3), randomized to teprotumumab (10 mg/kg IV every 3 weeks for 24 weeks) or intravenous methylprednisolone (500 mg weekly for 6 weeks), with primary outcome of ≥2 mm reduction in proptosis at 24 weeks, and secondary outcomes of CAS, quality of life, and relapse rate at 52 weeks.
A prospective cohort could determine real-world effectiveness and long-term outcomes of teprotumumab in diverse clinical settings.
A prospective cohort of 500 TED patients treated with teprotumumab across 15 centers, tracking proptosis, diplopia, TRAb levels, and adverse events (e.g., hearing loss, hyperglycemia) for 3 years, stratified by baseline disease severity and prior steroid use.
A case-control study could identify predictors of non-response to teprotumumab by comparing responders and non-responders.
A case-control study comparing 50 TED patients who achieved ≥3 mm proptosis reduction with teprotumumab to 50 non-responders, analyzing baseline serum biomarkers (IGF-1, TRAb, cytokines), orbital MRI features, and IGF-1R expression levels.
A cross-sectional study could describe the prevalence of teprotumumab use and reported outcomes in clinical practice.
A cross-sectional survey of 200 ophthalmology clinics in North America and Europe, collecting data on number of TED patients treated with teprotumumab, average proptosis reduction, and frequency of adverse events reported in routine practice.